Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 2
2(40.0%)
5Total
N/A(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04608604Not ApplicableCompleted

Mobility in Atypical Parkinsonism: a Trial of Physiotherapy

Role: collaborator

NCT06360887Not Yet Recruiting

Management of Proximal Humerus Fractures in Adults: a Clinical Trial

Role: lead

NCT01186809Phase 2Completed

Cytokine Induced Killer (CIK) Cells In Leukemia Patients

Role: collaborator

NCT01356446Not ApplicableWithdrawn

Checklist Application and Mortality

Role: lead

NCT01343069Not ApplicableWithdrawn

Safety Improvement and Checklist Application

Role: lead

NCT00354822Phase 2Terminated

Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.

Role: collaborator

All 6 trials loaded